...Inc. unit of Roche (SIX:ROG; OTCQX:RHBBY), which gained the compound through its 2007 acquisition of Tanox Inc....

...is only Genentech's second acquisition in its 38-year history: It paid roughly $919 million for Tanox Inc....
...that deal was to simplify marketing arrangements for asthma drug Xolair omalizumab, which Genentech and Tanox...

...deal will be the unit’s second acquisition; the first was infectious disease and oncology company Tanox Inc....

...deal will be the unit's second acquisition; the first was infectious disease and oncology company Tanox Inc....

...commercialize ibalizumab from Roche's Genentech unit, which gained the compound through its 2007 acquisition of Tanox Inc....

...Inc. unit of Roche (SIX:ROG; OTCQX:RHBBY), which gained the compound through its 2007 acquisition of Tanox Inc....

...2009 acquisition of Genentech Inc. Genentech had acquired the compound through its 2006 acquisition of Tanox Inc....

...Tanox Inc. in 2000 at $244.2 million. At IPO, Talecris was valued at $2.3 billion, and Tanox...

...which nine were sizable and three were valued above $500 million, including its acquisition of Tanox Inc....

...The offering does give Ironwood the second largest post-IPO valuation for a development-stage company, behind Tanox Inc....